AFR Exclusive, page-65

So now the ridiculously low AN1 SP is the fault of shareholders who fail to recognise the potential that you say still exists in holding the MK patent portfolio. A few years ago, you blamed HC downrampers for the falling CDY SP.

Both times, you are wrong. With regard to your HC downrampers, I said at the time that if you thought that HC posts were so effective in shareprice movement, then you should post your upramps more often. After all, you know more about the Company than most others, and I am sure you could debate anybody with a different point of view into the ground. But the plain fact is , your HC posts have never raised the shareprice. So why should other posts be able to lower it against yours? I am talking about significant continual rises.Significant continual lowerings.

HC posts are predominately reactive. They do not raise or lower the shareprice. What will raise or lower the shareprice will be Company announcements and Trade Journal and Financial Publication Reviews. With regard to the potential that you say still exists in holding the MK patent portfolio, the ridiculously low shareprice could be raised by, say for example, CSL, Pfizer, Lederle, or J & J, or some other Global Biotech, announcing that it recognises the potential that still exists in the MK patent portfolio. Now that should interest you.

Essentially, you have been posting to the wrong people. Forget HC. It has never worked for you with CDY/AN1. Look at the poster who is posting about QVC. No luck at all for him either, yet he also misguidedly blames other posters in his frustration about the low SP..Have you yourself considered contacting Global Biotechs, Medical Journals, financial Review Publications and telling them about the potential that you say exists in the MK patent portfolio? I am sure that few, if any, people in those Boardrooms read HC AN1 posts. They would naturally welcome your firsthand knowledge and experience. That way you might have a better chance of getting the SP moving up. Helpful? Clear?